AstraZeneca PLC - American Depositary Shares (AZN)
79.17
+0.00 (0.00%)
NASDAQ · Last Trade: Aug 18th, 8:29 AM EDT
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZenecastocktwits.com
Via Stocktwits · August 18, 2025
Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.
Via Stocktwits · August 15, 2025
White House trade adviser Peter Navarro discusses tariffs on pharma imports under a "Section 232" trade investigation.
Via Benzinga · August 14, 2025
Economists and investors are increasingly sounding the alarm over the growing risk of "stagflation," a perilous economic phenomenon characterized by high inflation coupled with stagnant economic growth. At the heart of these concerns are the tariff policies enacted by former President Donald Trump, which many experts fear could simultaneously drive
Via MarketMinute · August 11, 2025
AstraZeneca CEO Calls US Drug Pricing Model ‘Unsustainable’ — Pushes for Global Rate Alignmentstocktwits.com
Via Stocktwits · July 29, 2025
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheersstocktwits.com
Via Stocktwits · July 29, 2025
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to district court for further proceedings.
Via Benzinga · August 11, 2025
The global financial markets are grappling with a growing sense of unease as recent economic data points to a troubling confluence of high inflation and sluggish growth, rekindling fears of stagflation. Weaker-than-expected figures from key indicators, including the ISM Services index, the latest jobs report, and the US trade deficit,
Via MarketMinute · August 6, 2025
This developmental biotech is nearing a key inflection point.
Via The Motley Fool · August 6, 2025
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZenecastocktwits.com
Via Stocktwits · August 5, 2025
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose.
Via Benzinga · August 5, 2025
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.
Via Benzinga · August 1, 2025
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinchstocktwits.com
Via Stocktwits · July 31, 2025
Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.
Via The Motley Fool · July 29, 2025
AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer.
Via Benzinga · July 29, 2025
AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients.
Via Benzinga · July 28, 2025
Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them!
Via The Motley Fool · July 25, 2025
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.
Via Benzinga · July 24, 2025
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via Benzinga · July 22, 2025
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.
Via Benzinga · July 22, 2025
While Dow Jones futures were down 0.01% at the time of writing, the S&P 500 futures fell 0.09%.
Via Stocktwits · July 22, 2025
At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia.
Via Stocktwits · July 21, 2025